An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies

Kerstin Iffland, Franjo Grotenhermen, Kerstin Iffland, Franjo Grotenhermen

Abstract

Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy and psychotic disorders. Here, the most commonly reported side effects were tiredness, diarrhea, and changes of appetite/weight. In comparison with other drugs, used for the treatment of these medical conditions, CBD has a better side effect profile. This could improve patients' compliance and adherence to treatment. CBD is often used as adjunct therapy. Therefore, more clinical research is warranted on CBD action on hepatic enzymes, drug transporters, and interactions with other drugs and to see if this mainly leads to positive or negative effects, for example, reducing the needed clobazam doses in epilepsy and therefore clobazam's side effects. Conclusion: This review also illustrates that some important toxicological parameters are yet to be studied, for example, if CBD has an effect on hormones. Additionally, more clinical trials with a greater number of participants and longer chronic CBD administration are still lacking.

Keywords: cannabidiol; cannabinoids; medical uses; safety; side effects; toxicity.

Conflict of interest statement

EIHA paid nova-Institute for the review. F.G. is Executive Director of IACM.

References

    1. Bergamaschi MM, Queiroz RH, Zuardi AW, et al. . Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6:237–249
    1. Grotenhermen F, Müller-Vahl K. Cannabis und Cannabinoide in der Medizin: Fakten und Ausblick. Suchttherapie. 2016;17:71–76
    1. Hampson AJ, Grimaldi M, Axelrod J, et al. . Cannabidiol and Δ9-tetrahydrocannabinol are neuroprotective antioxidants. PNAS. 1998;95:8268–8273
    1. Oláh A, Tóth BI, Borbíró I, et al. . Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014:124:3713.
    1. Deiana S, Watanabe A, Yamasaki Y, et al. . Plasma and brain pharmacokinetic profile of Cannabidiol (CBD), cannabidivarine (CBDV), Delta (9)-tetrahydrocannabivarin (Δ9-THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive compulsive behaviour. Psychopharmacology. 2012;219:859–873
    1. Consroe P, Laguna J, Allender J, et al. . Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Beh. 1991;40:701–708
    1. Bih CI, Chen T, Nunn AV, et al. . Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12:699–730
    1. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46:86–95
    1. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. . Distinct effects of D9-tetrahydro-cannabinoland cannabidiol on neural activation during emotional processing. Arch Gen Psychiat. 2009;66:9–5.
    1. Manini AF, Yiannoulos G, Bergamaschi MM, et al. . Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2014;9:204–210
    1. Monographie NN. Cannabidiol. Deutscher Arzneimittel-Codex (DAC) inkl. Neues Rezeptur-Formularium (NRF). DAC/NRF October 22, 2015
    1. Pelkonen O, Mäeenpäeä J, Taavitsainen P, et al. . Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998;28:1203–1253
    1. Karlgren M, Bergström CA. How physicochemical properties of drugs affect their metabolism and clearance. In: New horizons in predictive drug metabolism and pharmacokinetics. Royal Society of Chemistry: Cambridge, UK, 2015.
    1. Ujváry I, Hanuš L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 2016;1:90–101
    1. Bornheim LM, Everhart ET, Li J, et al. . Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol. 1994;48:161–171
    1. Brzozowska N, Li KM, Wang XS, et al. . ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. Peer J. 2016;4:e208–1.
    1. Feinshtein V, Erez O, Ben-Zvi Z, et al. . Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. Am J Obstet Gynecol. 2013;209:573-e1
    1. Linge R, Jiménez-Sánchez L, Campa L, et al. . Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT 1A receptors. Neuropharmacology. 2016;103:16–26
    1. Schiavon AP, Bonato JM, Milani H, et al. . Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Prog Neuropsychopharmacol. 2016;64:27–34
    1. Peres FF, Levin R, Almeida V, et al. . Cannabidiol, among other cannabinoid drugs, modulates prepulse inhibition of startle in the SHR animal model: implications for schizophrenia pharmacotherapy. Front Pharmacol. 2016;7:30–3.
    1. Gomes FV, Issy AC, Ferreira FR, et al. . Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. J Neuropsychopharmacol. 2015;18:pyu04–1.
    1. Valvassori SS, Elias G, de Souza B, et al. . Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol. 2011;25:274–280
    1. Ren Y, Whittard J, Higuera-Matas A, et al. . Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci. 2009;29:14764–14769
    1. Sun S, Hu F, Wu J, Zhang S. Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons. Redox Biol. 2017;11:577–585
    1. Schurr A, Livne A. Differential inhibition of mitochondrial monoamine oxidase from brain by hashish components. Biochem Pharmacol. 1976;25:1201–1203
    1. Alvarez FJ, Lafuente H, Rey-Santano MC. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxicischemic newborn piglets. Pediatr Res. 2008;64:653–658
    1. Valvassori SS, Bavaresco DV, Scaini G. Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. Rev Bras Psiquiatr. 2013;35:380–386
    1. Scott KA, Dennis JL, Dalgleish AG, et al. . Inhibiting heat shock proteins can potentiate the cytotoxic effect of cannabidiol in human glioma cells. Anticancer Res. 2015;35:5827–5837
    1. Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23:1377–1385
    1. McAllister SD, Soroceanu L, Desprez PY. The antitumor activity of plant-derived non-psychoactive cannabinoids. J Neuroimmune Pharmacol. 2015;10:255–267
    1. Cheng D, Spiro AS, Jenner AM, et al. . Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. J Alzheimers Dis. 2014;42:1383–1396
    1. Weiss L, Zeira M, Reich S, et al. . Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology. 2008;54:244–249
    1. Hammell DC, Zhang LP, Ma F, et al. . Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2015;20:936–948
    1. Murase R, Limbad C, Murase R. Id-1 gene and protein as novel therapeutic targets for metastatic cancer. Cancer Res. 2012;72:530–8.
    1. Paria BC, Das SK, Dey SK. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. PNAS. 1995;92:9460–9464
    1. Leanza L, Managò A, Zoratti M, et al. . Pharmacological targeting of ion channels for cancer therapy: in vivo evidences. Biochim Biophys Acta. 2016;1863:1385–1397
    1. Ramer R, Merkord J, Rohde H, et al. . Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol. 2010;79:955–966
    1. Ramer R, Bublitz K, Freimuth N. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012;26:1535–1548
    1. Benhamou Y. Gene and protein as novel therapeutic targets for metastatic cancer. Available at (accessed on October1, 2016)
    1. McAllister SD, Christian RT, Horowitz MP. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther. 2007;6:2921–2927
    1. De Petrocellis L, Ligresti A, Schiano Moriello A, et al. . Non-Δ9-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol. 2013;168:79–102
    1. Fowler CJ. Delta9-tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: a critical examination of the preclinical literature. Pharmacol Ther. 2015;97:587–596
    1. Aviello G, Romano B, Borrelli F, et al. . Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med. 2012;90:925–934
    1. Jadoon KA, Ratcliffe SH, Barrett DA. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39:1777–1786
    1. Watanabe K, Motoya E, Matsuzawa N, et al. . Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology. 2005;206:471–478
    1. Narimatsu S, Watanabe K, Yamamoto I. Inhibition of hepatic microsomal cytochrome P450 by cannabidiol in adult male rats. Chem Pharm Bull. 1990;38:1365–1368
    1. Jones NA, Hill AJ, Smith I, et al. . Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharm Ex Ther. 2010;332:569–577
    1. Jones NA, Glyn SE, Akiyama S, et al. . Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21:344–352
    1. Fasinu PS, Phillips S, ElSohly MA, et al. . Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy. 2016;36:781–796
    1. Persson A, Ingelman-Sundberg M. Pharmacogenomics of cytochrome P450 dependent metabolism of endogenous compounds: implications for behavior, psychopathology and treatment. J Pharmacogenomics Pharmacoproteomics 2014;5:12–7.
    1. Ghosh C, Hossain M, Solanki J, et al. . Pathophysiological implications of neurovascular P450 in brain disorders. Drug Discov Today. 2016;21:1609–1619
    1. Brunt TM, van Genugten M, Höner-Snoeken K, et al. . Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis. J Clin Psychopharmacol. 2014;34:344–349
    1. Das RK, Kamboj SK, Ramadas M, et al. . Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology. 2013;226:781–792
    1. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. . Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35:764–774
    1. Martin-Santos R, Crippa J, Batalla A. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des. 2012;18:4966–4979
    1. Crippa JAS, Hallak JEC, Machado-de-Sousa JP, et al. . Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther. 2013;38:162–164
    1. Morgan CJ, Freeman TP, Schafer GL. Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010;35:1879–1885
    1. Hurd YL, Yoon M, Manini AF. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics. 2015;12:807–815
    1. Morgan CJ, Das RK, Joye A, et al. . Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addictive Behav. 2013;38:2433–2436
    1. Zuardi AW, Guimaraes FS, Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res. 1993;26:213–217
    1. Appiah-Kusi E, Mondelli V, McGuire P, et al. . Effects of cannabidiol treatment on cortisol response to social stress in subjects at high risk of developing psychosis. Psychoneuroendocrinology. 2016;7(Supplement):23–24
    1. Geffrey AL, Pollack SF, Bruno PL, et al. . Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246–1251
    1. Grotenhermen F, Gebhardt K, Berger M. Cannabidiol. Nachtschatten Verlag: Solothurn, Switzerland, 2016.
    1. Mincis M, Pfeferman A, Guimarães RX. Chronic administration of cannabidiol in man. Pilot study. AMB Rev Assoc Med Bras. 1973;19:185–190
    1. Cunha J, Carlini EA, Pereira AE, et al. . Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21:175–185
    1. Zuardi AW, Crippa JAS, Hallak JEC, et al. . Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol. 2009;3:979–983
    1. Leweke FM, Piomelli D, Pahlisch F. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl psychiatry. 2012;2:e9–4.
    1. Leweke F, Koethe D, Gerth C. Cannabidiol as an antipsychotic: a double-blind, controlled clinical trial of cannabidiol versus amisulpiride in acute schizophrenia. In: 15th annual symposium on cannabinoids Cannabinoid Research Society: Clearwater Beach, FL, 2005.
    1. Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015;162:153–161
    1. Zuardi AW, Crippa JAS, Dursun SM, et al. . Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol. 2010;24:135–137
    1. Braga RJ, Abdelmessih S, Tseng J, et al. . Cannabinoids and bipolar disorder. Cannabinoids in neurologic and mental disease. Elsevier, Amsterdam, 2015, p. 205
    1. Devinsky O, Marsh E, Friedman D, et al. . Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270–278
    1. Chagas MHN, Zuardi AW, Tumas V, et al. . Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28:1088–1098
    1. Yeshurun M, Shpilberg O, Herscovici C, et al. . Cannabidiol for the prevention of graft-versus- host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study. Biol Blood Marrow Transplant. 2015;21:1770–1775

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe